Glenmark Pharma USA Launches Methylene Blue Injection

Glenmark Pharmaceuticals Inc., USA has announced the launch of Methylene Blue Injection USP, 50 mg/10 mL (5 mg/mL) Single-Dose Vial. This product is bioequivalent and therapeutically equivalent to Provepharm SAS's ProvayBlue® Injection. The market for ProvayBlue® Injection achieved approximately $19.0 million in annual sales for the 12-month period ending April 2026, according to IQVIA® data. This launch is part of Glenmark's strategy to expand its institutional portfolio and provide affordable medicine options in the U.S. market.